Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

<h4>Background</h4>Recent studies have suggested that higher serum cholesterol may be associated with lower occurrence of Parkinson's disease (PD). This study is to test the hypothesis that higher serum cholesterol correlates with slower PD progression.<h4>Methods</h4>Ba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuemei Huang, Peggy Auinger, Shirley Eberly, David Oakes, Michael Schwarzschild, Alberto Ascherio, Richard Mailman, Honglei Chen, Parkinson Study Group DATATOP Investigators
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee0abda32faa415cbaf71872196d95ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee0abda32faa415cbaf71872196d95ce
record_format	dspace
spelling	oai:doaj.org-article:ee0abda32faa415cbaf71872196d95ce2021-11-18T06:48:09ZSerum cholesterol and the progression of Parkinson's disease: results from DATATOP.1932-620310.1371/journal.pone.0022854https://doaj.org/article/ee0abda32faa415cbaf71872196d95ce2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21853051/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Recent studies have suggested that higher serum cholesterol may be associated with lower occurrence of Parkinson's disease (PD). This study is to test the hypothesis that higher serum cholesterol correlates with slower PD progression.<h4>Methods</h4>Baseline non-fasting serum total cholesterol was measured in 774 of the 800 subjects with early PD enrolled between 1987 and 1988 in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. Participants were followed for up to two years, with clinical disability requiring levodopa therapy as the primary endpoint. Hazard ratios (HRs) and 95% confidence intervals (CI) were determined for increasing serum cholesterol concentration (in quintiles) for clinical disability requiring levodopa therapy, after adjusting for confounders. At baseline, only nine subjects reported use of cholesterol-lowering agents (two with statins).<h4>Results</h4>The overall mean cholesterol level was 216 mg/dL (range 100-355). The HR of progressing to the primary endpoint decreased with increasing serum cholesterol concentrations. Compared to the lowest quintile, the HRs (95%CI), for each higher quintile (in ascending order) are 0.83 (0.59-1.16); 0.86 (0.61-1.20); 0.84 (0.60-1.18); and 0.75 (0.52-1.09). The HR for one standard deviation (SD) increase = 0.90 [(0.80-1.01), p for trend = 0.09]. This trend was found in males (HR per SD = 0.88 [(0.77-1.00), p for trend = 0.05], but not in females [HR = 1.03 (0.81-1.32)].<h4>Conclusions</h4>This secondary analysis of the DATATOP trial provides preliminary evidence that higher total serum cholesterol concentrations may be associated with a modest slower clinical progression of PD, and this preliminary finding needs confirmation from larger prospective studies.Xuemei HuangPeggy AuingerShirley EberlyDavid OakesMichael SchwarzschildAlberto AscherioRichard MailmanHonglei ChenParkinson Study Group DATATOP InvestigatorsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 8, p e22854 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xuemei Huang Peggy Auinger Shirley Eberly David Oakes Michael Schwarzschild Alberto Ascherio Richard Mailman Honglei Chen Parkinson Study Group DATATOP Investigators Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
description	<h4>Background</h4>Recent studies have suggested that higher serum cholesterol may be associated with lower occurrence of Parkinson's disease (PD). This study is to test the hypothesis that higher serum cholesterol correlates with slower PD progression.<h4>Methods</h4>Baseline non-fasting serum total cholesterol was measured in 774 of the 800 subjects with early PD enrolled between 1987 and 1988 in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. Participants were followed for up to two years, with clinical disability requiring levodopa therapy as the primary endpoint. Hazard ratios (HRs) and 95% confidence intervals (CI) were determined for increasing serum cholesterol concentration (in quintiles) for clinical disability requiring levodopa therapy, after adjusting for confounders. At baseline, only nine subjects reported use of cholesterol-lowering agents (two with statins).<h4>Results</h4>The overall mean cholesterol level was 216 mg/dL (range 100-355). The HR of progressing to the primary endpoint decreased with increasing serum cholesterol concentrations. Compared to the lowest quintile, the HRs (95%CI), for each higher quintile (in ascending order) are 0.83 (0.59-1.16); 0.86 (0.61-1.20); 0.84 (0.60-1.18); and 0.75 (0.52-1.09). The HR for one standard deviation (SD) increase = 0.90 [(0.80-1.01), p for trend = 0.09]. This trend was found in males (HR per SD = 0.88 [(0.77-1.00), p for trend = 0.05], but not in females [HR = 1.03 (0.81-1.32)].<h4>Conclusions</h4>This secondary analysis of the DATATOP trial provides preliminary evidence that higher total serum cholesterol concentrations may be associated with a modest slower clinical progression of PD, and this preliminary finding needs confirmation from larger prospective studies.
format	article
author	Xuemei Huang Peggy Auinger Shirley Eberly David Oakes Michael Schwarzschild Alberto Ascherio Richard Mailman Honglei Chen Parkinson Study Group DATATOP Investigators
author_facet	Xuemei Huang Peggy Auinger Shirley Eberly David Oakes Michael Schwarzschild Alberto Ascherio Richard Mailman Honglei Chen Parkinson Study Group DATATOP Investigators
author_sort	Xuemei Huang
title	Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
title_short	Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
title_full	Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
title_fullStr	Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
title_full_unstemmed	Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
title_sort	serum cholesterol and the progression of parkinson's disease: results from datatop.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/ee0abda32faa415cbaf71872196d95ce
work_keys_str_mv	AT xuemeihuang serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT peggyauinger serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT shirleyeberly serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT davidoakes serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT michaelschwarzschild serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT albertoascherio serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT richardmailman serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT hongleichen serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop AT parkinsonstudygroupdatatopinvestigators serumcholesterolandtheprogressionofparkinsonsdiseaseresultsfromdatatop
_version_	1718424389484019712

Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

Ejemplares similares